drugset

drugset / Trial / NCT01452828

A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

NCT01452828 ↗

Phase 1 Completed 24 enrolled Merck & Co., Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the single dose pharmacokinetics (PK) and safety of TR701 FA in subjects with advance renal impairment.

Timeline

Start: 2011-10
Primary completion: 2012-03
Completion: 2012-03

Publications

Flanagan S, Minassian SL, Morris D, Ponnuraj R, Marbury TC, Alcorn HW, Fang E, Prokocimer P. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. Antimicrob Agents Chemother. 2014 Nov;58(11):6471-6. doi: 10.1128/AAC.03431-14. Epub 2014 Aug 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tedizolid	Small molecule	200 mg	Intravenous

Indications